ClinicalTrials.gg
CompletedNCT01599325Updated Mar 19, 2019Results posted

Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome

A Phase 2 interventional study of Azacitidine in Myelodysplastic Syndrome (MDS), sponsored by Celgene. Completed at 11 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-19.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.

Enrollment
28th of 126
72 · median 38
Started
2012
with 9 others
Phase 2
63 of 130
5 open now
Registered
58th of 130
by date
Lead sponsor
14 of 130
Celgene

Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 28th largest by enrollment of the 126 interventional ones that give a count, is one of 10 that started in 2012, is one of 63 in phase 2, and was the 58th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing azacitidine in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

The purpose of the study is to determine whether azacitidine is safe and effective in the treatment of Chinese patients with higher risk Myelodysplastic Syndromes (MDS).

03

Conditions studied

  • Myelodysplastic Syndrome (MDS)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must satisfy the following criteria to be enrolled in the study:

  • Chinese males and females of Asian descent ≥ 18 years of age at the time of signing the document;
  • Must have a documented diagnosis of anemia with excess blasts (RAEB) or refractory anemia with excess blasts in transformation (RAEB-T) according to French-American-British (FAB) classification for Myelodysplastic Syndrome (MDS) and with an International Prognostic Scoring System (IPSS) score of intermediate-2 or high risk or a diagnosis of myelodysplastic chronic myelomonocytic leukemia (CMML) per modified FAB criteria meeting the following:

    • Monocytosis in peripheral blood > 1 x 10\^9/L;
    • Dysplasia in one or more myeloid cell lines;
    • 10% to 29% blasts in the bone marrow; and White blood cell (WBC) count \< 13 x 10\^9/L
  • (ECOG) performance status of 0, 1, or 2 ;
  • Adequate organ function, defined as:
  • Serum ≤ 1.5 times the (ULN);
  • Serum (AST) and alanine aminotransferase (ALT) ≤ 2.0 times the ULN;
  • Serum Creatinine ≤ 1.5 times the ULN;
  • Females of (FCBP) must:
  • Agree to the use of a physician-approved method (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on azacitidine; and
  • for 3 months following the last dose of azacitidine; and have a negative serum pregnancy test within 72 hours prior to starting Product (IP).
  • Male subjects with a female partner of childbearing potential must agree to the use of a physician-approved contraceptive method throughout the course of the study and avoid fathering a child during the course of the study and for 3 months following the last dose of azacitidine;
  • Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted;
  • Able to adhere to the study visit schedule and other protocol requirements.

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  • Previous treatment with azacitidine or decitabine;
  • Diagnosis of malignant disease within the previous 12 months (excluding basal cell carcinoma of the skin without complications, "in-situ" carcinoma of the cervix or breast, or other local excised or irradiated with a high probability of cure);
  • Uncorrected red cell folate deficiency or vitamin B12 deficiency;
  • Diagnosis of disease;
  • Malignant hepatic tumors;
  • Known or suspected to azacitidine or mannitol;
  • Candidate to proceed to bone marrow or stem cell transplant during the study;
  • Prior transplantation or cytotoxic therapy, including azacitidine and chemotherapy, administered to treat MDS;
  • Treatment with erythropoietin or myeloid growth factors (granulocyte colony-stimulating factor [G-CSF] or granulocyte-macrophage colony-stimulating factor [GM-CSF]) during the 21 days prior to Day 1 of Cycle 1;
  • Treatment with androgenic hormones during the 14 days prior to Day 1 of Cycle 1;
  • Active viral infection with known (HIV) or viral hepatitis type B or C;
  • Treatment with other drugs, including thalidomide and arsenic trioxide, within the previous 30 days prior to Day 1 of Cycle 1, or ongoing adverse events from previous treatment with investigational drugs, regardless of the time period; and
  • Pregnant or lactating females;
  • Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study;
  • Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study;
  • Any condition that confounds the ability to interpret data from the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Azacitidine

    Azacitidine 75 mg/m\^2/day subcutaneously (SC) for 7 days every 28 days until disease progression (DP), adverse events (AE), withdrawal of consent from further treatment, withdrawal of consent, death, lost to follow-up, or protocol violation.

    Drug: Azacitidine

Interventions

  • Subcutaneous administration of azacitidine 75 mg/m\^2/day for 7 days every 28 days optimally for at least 6 cycles until disease progression, unacceptable toxicity, or treatment discontinuation for any other reason

    Also known as: Vidaza

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Hematologic Response Based on the International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS) and Programmatically Assessed by the Sponsor Using Clinically Relevant Data.

    Hematologic Response is defined by those participants who experienced a Complete Response, Partial Response and Stable Disease (SD) based on IWG 2000 response criteria for MDS. CR = repeat bone marrow (BM) shows \<5% myeloblasts, and peripheral blood values lasting ≥ 2 months of hemoglobin (hgb) (\>110 g/L), neutrophils (≥1.5x10\^9/L), platelets (≥100x10\^9/L), blasts (0%) and no dysplasia • PR = same as CR for peripheral blood: BM shows blasts decrease by ≥ 50% or a less advanced FAB classification from pretreatment • Stable disease (SD): failure to achieve a PR, no evidence of progression for at least 2 months. • Failure: death during treatment or disease progression • Relapse After CR or PR: return to pretreatment BM blast percent or decrement of ≥ 50% from remission/response levels in granulocytes or platelets; or reduction in hgb by ≥20 g/L or transfusion dependence • Disease Progression: change in blast levels • Disease Transformation to Acute Myelogenous Leukemia.

    Time frame: Response initially assessed at end of cycle 6, then every 4 cycles; Up to 29 January 2015; 894 days

  2. Percentage of Participants With a Hematologic Response Using IWG Criteria for MDS and Assessed by the Investigator

    Hematologic Response is defined by those participants who experienced a Complete Response, Partial Response and Stable Disease (SD) based on IWG 2000 response criteria for MDS. CR = repeat bone marrow (BM) shows \<5% myeloblasts, and peripheral blood values lasting ≥ 2 months of hemoglobin (hgb) (\>110 g/L), neutrophils (≥1.5x10\^9/L), platelets (≥100x10\^9/L), blasts (0%) and no dysplasia • PR = same as CR for peripheral blood: BM shows blasts decrease by ≥ 50% or a less advanced FAB classification from pretreatment • Stable disease (SD): failure to achieve a PR, no evidence of progression for at least 2 months. • Failure: death during treatment or disease progression • Relapse After CR or PR: return to pretreatment BM blast percent or decrement of ≥ 50% from remission/response levels in granulocytes or platelets; or reduction in hgb by ≥20 g/L or transfusion dependence • Disease Progression: change in blast levels • Disease Transformation to Acute Myelogenous Leukemia.

    Time frame: Response initially assessed at end of cycle 6, then every 4 cycles; Up to 29 January 2015; 894 days

  3. Percentage of Participants Achieving a Hematologic Improvement (HI) Based on 2000 IWG Response Criteria for MDS and Programmatically Assessed by the Sponsor Using Clinically Relevant Data.

    Hematologic improvements (HI) have 4 categories: 1. Erythroid response (HI-E): Major \>20g/L increase or transfusion independent. Minor: 10-20g/L increase or ≥50% decrease in transfusion requirements. 2. Platelet response (HI-P): Major absolute increase of ≥30x10\^9/L or platelet transfusion independence. Minor: ≥50% increase. 3. Neutrophil response (HI-N): Major 100% increase or an absolute increase of \>0.5x10\^9/L. Minor: ≥100% increase and absolute increase of \<0.5x10\^9/L 4. Progression or relapse after HI Hematological improvement (HI) was defined as any type (major or minor) of improvement of HI-E, HI-P, or HI-N. Criteria: Pretreatment=hemoglobin \<100g/L or RBC transfusion-dependent, platelet count \<100x10\^9/L or platelet transfusion dependent, absolute neutrophil count \<1.5x10\^9/L. Sponsor's determination was derived using clinically relevant data. Denominator for progression/relapse after HI included participants who had achieved HI.

    Time frame: Up to 29 January 2015; 894 days

Secondary outcomes

  1. The Number of Units of Platelet Transfusions by Cycle

    The number of units of platelet transfusions received 56 days prior to treatment, considered the baseline period, (baseline period defined as the screening period before the date of the first dose of azacitidine; any laboratory and blood transfusion data reported on the day of the first dose of azacitidine was considered to be baseline data) and during study was standardized per 28 days and summarized by cycle for platelets. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length.

    Time frame: Up to cycle 27; The on-treatment period was considered the period from the date of first dose to the last treatment study visit; Up to 29 January 2015; 894 days

  2. The Number of Platelet Transfusions by Cycle

    The number of platelet transfusions received 56 days prior to treatment, considered the baseline period (baseline period defined as the screening period before the date of the first dose of azacitidine; any laboratory and blood transfusion data reported on the day of the first dose of azacitidine was considered to be baseline data) and during study was standardized per 28 days and summarized by cycle for platelets. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length.

    Time frame: Up to cycle 27; The on-treatment period was considered the period from the date of first dose to the last treatment study visit; Up to 29 January 2015; 894 days

  3. The Number of Units of Red Blood Cell (RBC) Transfusions by Cycle

    The number of units of RBC received 56 days prior to treatment, considered the baseline period (baseline period defined as the screening period before the date of the first dose of azacitidine; any laboratory and blood transfusion data reported on the day of the first dose of azacitidine was considered to be baseline data) and during study was standardized per 28 days and summarized by cycle for RBC. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length.

    Time frame: Up to cycle 27; The on-treatment period was considered the period from the date of first dose to the last treatment study visit; Up to 29 January 2015; 894 days

  4. The Number of RBC Transfusions by Cycle

    The number of RBC transfusions received 56 days prior to treatment, considered the baseline period (baseline period defined as the screening period before the date of the first dose of azacitidine; any laboratory and blood transfusion data reported on the day of the first dose of azacitidine was considered to be baseline data) and during study was standardized per 28 days and summarized by cycle for platelets. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length.

    Time frame: Up to cycle 27; The on-treatment period was considered the period from the date of first dose to the last treatment study visit; Up to 29 January 2015; 894 days

  5. The Number of Infections (Post-baseline Average) Requiring Intravenous (IV) Antibiotics, Anti-fungals, or Antivirals by Cycle

    The on-treatment adverse event of infection requiring IV antibiotics, antifungals, or antivirals per 28 days/cycle. The overall post-baseline average is the average of number of infections requiring IV antibiotics or IV antiviral per 28 days/cycle.

    Time frame: Up to cycle 27; The on-treatment period was considered the period from the date of first dose to the last treatment study visit; Up to 29 January 2015; 894 days

  6. Kaplan Meier Estimates for Overall Survival (OS)

    Overall survival is defined as time to death from any cause, is calculated using date of first dose and date of death, or date of last follow-up for censored participants. Those, who die regardless of the cause of death, will be considered to have an event.

    Time frame: Until the end of the survival follow-up period; Up to data cut-off of 29 January 2015; 894 days

  7. Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Parent Phase

    A treatment-emergent adverse events (TEAE) was defined as AEs with an onset date on or after the date of first dose and within 28 days after the date of the last dose. Any AE that occurred beyond this timeframe and was assessed by the investigator as possibly related to study drug was considered treatment-emergent. The intensity and severity of AEs was assessed by the investigator according to the Common Terminology Criteria for Adverse Event (CTCAE) Version 4.0. For any AEs not listed in the CTCAE grading system, the intensities of these events was assessed by the Investigator using the 5-point scale: Grade 1 = Mild, Grade 2 = Moderate; Grade 3 = Severe, Grade 4 = Life threatening, Grade 5 = Death. An SAE is any AE occurring that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and constitutes an important medical event.

    Time frame: Up to 29 January 2015; from the first dose of study drug to 28 days after the date of the last dose of study drug (maximum time on study was 244 days)

  8. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Azacitidine

    Area under the plasma concentration-time curve from time zero to infinity (AUC∞) following multiple doses of Azacitidine on Day 7; if possible, the area under the concentration-time curve from time zero to infinity, calculated by the linear trapezoidal rule and extrapolated to infinity was calculated according to the following equation: AUC∞ = AUCt + (Ct/ λz ), where Ct is the last quantifiable concentration. No AUC extrapolation will be performed with unreliable λz. If % AUC extrapolated is ≥ 25%, AUC∞ will not be reported

    Time frame: PK blood samples collected at 0.25, 0.5, 1,2,3,4, 6 and 8 hours after azacitidine administration on Day 7

  9. Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Azacitidine

    Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear trapezoidal rule when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing.

    Time frame: PK blood samples collected at 0.25, 0.5, 1,2,3,4, 6 and 8 hours after azacitidine administration on Day 7

  10. Maximum Observed Plasma Concentration (Cmax) of Azacitidine

    The observed maximum plasma concentration obtained directly from the observed concentration versus time data.

    Time frame: PK blood samples collected at 0.25, 0.5, 1,2,3,4, 6 and 8 hours after azacitidine administration on Day 7

  11. Time to Maximum Plasma Concentration (Tmax) of Azacitidine

    Time to maximum observed plasma concentration obtained directly from the observed concentration versus time data.

    Time frame: PK blood samples collected at 0.25, 0.5, 1,2,3,4, 6 and 8 hours after azacitidine administration on Day 7

  12. Terminal Phase of Half-life (T1/2) of Azacitidine

    The apparent terminal half-life was calculated according to the following equation t½ = 0.693/λz.

    Time frame: PK blood samples collected at 0.25, 0.5, 1,2,3,4, 6 and 8 hours after azacitidine administration on Day 7

  13. Apparent Total Plasma Clearance (CL/F) of Azacitidine

    Apparent total plasma clearance (CL/F) of Azacitidine was calculated as Dose/AUC∞

    Time frame: PK blood samples collected at 0.25, 0.5, 1,2,3,4, 6 and 8 hours after azacitidine administration on Day 7

  14. Apparent Volume of Distribution (Vd/F) of Azacitidine

    Apparent volume of distribution, was calculated according to the equation: Vd/F = (CL/F)/λz

    Time frame: PK blood samples collected at 0.25, 0.5, 1,2,3,4, 6 and 8 hours after azacitidine administration on Day 7

  15. Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Extension Phase

    A treatment-emergent adverse events (TEAE) was defined as AEs with an onset date on or after the date of first dose and within 28 days after the date of the last dose. Any AE that occurred beyond this timeframe and was assessed by the investigator as possibly related to study drug was considered treatment-emergent. The intensity and severity of AEs was assessed by the investigator according to the Common Terminology Criteria for Adverse Event (CTCAE) Version 4.0. For any AEs not listed in the CTCAE grading system, the intensities of these events was assessed by the Investigator using the 5-point scale: Grade 1 = Mild, Grade 2 = Moderate; Grade 3 = Severe, Grade 4 = Life threatening, Grade 5 = Death. An SAE is any AE occurring that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and constitutes an important medical event.

    Time frame: Up to final data cut off date of 25 April 2018; from the first dose of study drug extesnion of 29 December 2014 to 28 days after the date of the last dose of study drug; median duration of any dose of study drug was 169 days

07

Results

Posted Feb 29, 2016

Participant flow

Primary Parent Phase
Participant flow — Primary Parent Phase
MilestoneAzacitidine
Started72
Intent to treat (itt) population72
Pharmacokinetic (pk) population12
Completed15
Not completed57
Withdrew: Adverse event5
Withdrew: Disease progression7
Withdrew: Withdrawal by subject20
Withdrew: Death13
Withdrew: Protocol violation1
Withdrew: Lack of therapeutic effect9
Withdrew: Other2
Extension Phase
Participant flow — Extension Phase
MilestoneAzacitidine
Started15
Completed0
Not completed15
Withdrew: Study closure1
Withdrew: Stopped to receive stem cell transplant1
Withdrew: Lack of therapeutic effect4
Withdrew: Disease progression1
Withdrew: Withdrawal by subject8

Outcome measures

PrimaryPercentage of Participants With a Hematologic Response Based on the International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS) and Programmatically Assessed by the Sponsor Using Clinically Relevant Data.

Hematologic Response is defined by those participants who experienced a Complete Response, Partial Response and Stable Disease (SD) based on IWG 2000 response criteria for MDS. CR = repeat bone marrow (BM) shows \<5% myeloblasts, and peripheral blood values lasting ≥ 2 months of hemoglobin (hgb) (\>110 g/L), neutrophils (≥1.5x10\^9/L), platelets (≥100x10\^9/L), blasts (0%) and no dysplasia • PR = same as CR for peripheral blood: BM shows blasts decrease by ≥ 50% or a less advanced FAB classification from pretreatment • Stable disease (SD): failure to achieve a PR, no evidence of progression for at least 2 months. • Failure: death during treatment or disease progression • Relapse After CR or PR: return to pretreatment BM blast percent or decrement of ≥ 50% from remission/response levels in granulocytes or platelets; or reduction in hgb by ≥20 g/L or transfusion dependence • Disease Progression: change in blast levels • Disease Transformation to Acute Myelogenous Leukemia.

Time frame:
Response initially assessed at end of cycle 6, then every 4 cycles; Up to 29 January 2015; 894 days
Reported as:
Number · percentage of participants
Percentage of Participants With a Hematologic Response Based on the International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS) and Programmatically Assessed by the Sponsor Using Clinically Relevant Data.
percentage of participantsAzacitidine
Overall CR+PR1.4 (0.0 to 7.5)
Overall CR+PR+SD95.8 (88.3 to 99.1)
Complete Remission (CR)1.4 (0.0 to 7.5)
Partial Remission (PR)0 (0.0 to 5.0)
PrimaryPercentage of Participants With a Hematologic Response Using IWG Criteria for MDS and Assessed by the Investigator

Hematologic Response is defined by those participants who experienced a Complete Response, Partial Response and Stable Disease (SD) based on IWG 2000 response criteria for MDS. CR = repeat bone marrow (BM) shows \<5% myeloblasts, and peripheral blood values lasting ≥ 2 months of hemoglobin (hgb) (\>110 g/L), neutrophils (≥1.5x10\^9/L), platelets (≥100x10\^9/L), blasts (0%) and no dysplasia • PR = same as CR for peripheral blood: BM shows blasts decrease by ≥ 50% or a less advanced FAB classification from pretreatment • Stable disease (SD): failure to achieve a PR, no evidence of progression for at least 2 months. • Failure: death during treatment or disease progression • Relapse After CR or PR: return to pretreatment BM blast percent or decrement of ≥ 50% from remission/response levels in granulocytes or platelets; or reduction in hgb by ≥20 g/L or transfusion dependence • Disease Progression: change in blast levels • Disease Transformation to Acute Myelogenous Leukemia.

Time frame:
Response initially assessed at end of cycle 6, then every 4 cycles; Up to 29 January 2015; 894 days
Reported as:
Number · percentage of participants
Percentage of Participants With a Hematologic Response Using IWG Criteria for MDS and Assessed by the Investigator
percentage of participantsAzacitidine
Overall CR+PR12.5 (5.9 to 22.4)
Overall CR+PR+SD70.8 (58.9 to 81.0)
CR6.9 (2.3 to 15.5)
PR5.6 (1.5 to 13.6)
PrimaryPercentage of Participants Achieving a Hematologic Improvement (HI) Based on 2000 IWG Response Criteria for MDS and Programmatically Assessed by the Sponsor Using Clinically Relevant Data.

Hematologic improvements (HI) have 4 categories: 1. Erythroid response (HI-E): Major \>20g/L increase or transfusion independent. Minor: 10-20g/L increase or ≥50% decrease in transfusion requirements. 2. Platelet response (HI-P): Major absolute increase of ≥30x10\^9/L or platelet transfusion independence. Minor: ≥50% increase. 3. Neutrophil response (HI-N): Major 100% increase or an absolute increase of \>0.5x10\^9/L. Minor: ≥100% increase and absolute increase of \<0.5x10\^9/L 4. Progression or relapse after HI Hematological improvement (HI) was defined as any type (major or minor) of improvement of HI-E, HI-P, or HI-N. Criteria: Pretreatment=hemoglobin \<100g/L or RBC transfusion-dependent, platelet count \<100x10\^9/L or platelet transfusion dependent, absolute neutrophil count \<1.5x10\^9/L. Sponsor's determination was derived using clinically relevant data. Denominator for progression/relapse after HI included participants who had achieved HI.

Time frame:
Up to 29 January 2015; 894 days
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Hematologic Improvement (HI) Based on 2000 IWG Response Criteria for MDS and Programmatically Assessed by the Sponsor Using Clinically Relevant Data.
percentage of participantsAzacitidine
Any improvement52.8 (40.7 to 64.7)
Hematologic Improvement-E (major)35.8 (24.5 to 48.5)
Hematologic Improvement-E (minor)9.0 (3.4 to 18.5)
Hematologic Improvement-P (major)37.9 (25.5 to 51.6)
Hematologic Improvement-P (minor)0.0 (0.0 to 6.2)
Hematologic Improvement-N (major)21.8 (11.8 to 35.0)
Hematologic Improvement-N (minor)0.0 (0.0 to 6.5)
SecondaryThe Number of Units of Platelet Transfusions by Cycle

The number of units of platelet transfusions received 56 days prior to treatment, considered the baseline period, (baseline period defined as the screening period before the date of the first dose of azacitidine; any laboratory and blood transfusion data reported on the day of the first dose of azacitidine was considered to be baseline data) and during study was standardized per 28 days and summarized by cycle for platelets. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length.

Time frame:
Up to cycle 27; The on-treatment period was considered the period from the date of first dose to the last treatment study visit; Up to 29 January 2015; 894 days
Reported as:
Mean · Units of platelet transfusions
The Number of Units of Platelet Transfusions by Cycle
Units of platelet transfusionsAzacitidine
Baseline N = 721.9 ± 4.91
Overall Post-Baseline Average N = 724.7 ± 17.79
Overall Change from Baseline N = 722.8 ± 17.89
Cycle 1 N = 725.2 ± 18.83
Cycle 22.4 ± 5.86
Cycle 33.3 ± 11.44
Cycle 42.7 ± 6.13
Cycle 52.5 ± 7.69
Cycle 61.5 ± 4.15
Cycle 71.0 ± 2.84
Cycle 81.1 ± 2.05
Cycle 90.8 ± 2.46
Cycle 100.8 ± 2.08
Cycle 110.5 ± 1.00
Cycle 120.3 ± 0.78
Cycle 130.3 ± 0.72
Cycle 140.1 ± 0.35
Cycle 150.3 ± 0.90
Cycle 160.3 ± 0.90
Cycle 170.3 ± 0.73
Cycle 180.6 ± 1.51
Cycle 190.3 ± 0.64
Cycle 200.2 ± 0.37
Cycle 210.0 ± 0.00
Cycle 220.0 ± NA
Cycle 230.0 ± NA
Cycle 240.0 ± NA
Cycle 250.0 ± NA
Cycle 260.0 ± NA
Cycle 270.0 ± NA
SecondaryThe Number of Platelet Transfusions by Cycle

The number of platelet transfusions received 56 days prior to treatment, considered the baseline period (baseline period defined as the screening period before the date of the first dose of azacitidine; any laboratory and blood transfusion data reported on the day of the first dose of azacitidine was considered to be baseline data) and during study was standardized per 28 days and summarized by cycle for platelets. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length.

Time frame:
Up to cycle 27; The on-treatment period was considered the period from the date of first dose to the last treatment study visit; Up to 29 January 2015; 894 days
Reported as:
Mean · Platelet transfusions
The Number of Platelet Transfusions by Cycle
Platelet transfusionsAzacitidine
Baseline N = 720.8 ± 2.36
Overall Post-Baseline Average N = 721.6 ± 2.83
Overall Change from Baseline N = 720.8 ± 3.29
Cycle 1 N = 721.8 ± 2.89
Cycle 21.3 ± 2.59
Cycle 31.2 ± 2.28
Cycle 41.3 ± 2.18
Cycle 50.9 ± 1.58
Cycle 60.7 ± 1.34
Cycle 70.8 ± 2.50
Cycle 80.8 ± 1.66
Cycle 90.8 ± 2.46
Cycle 100.8 ± 2.08
Cycle 110.5 ± 1.00
Cycle 120.3 ± 0.78
Cycle 130.3 ± 0.72
Cycle 140.1 ± 0.35
Cycle 150.3 ± 0.90
Cycle 160.3 ± 0.90
Cycle 170.3 ± 0.73
Cycle 180.6 ± 1.51
Cycle 190.3 ± 0.64
Cycle 200.2 ± 0.37
Cycle 210.0 ± 0.00
Cycle 220.0 ± NA
Cycle 230.0 ± NA
Cycle 240.0 ± NA
Cycle 250.0 ± NA
Cycle 260.0 ± NA
Cycle 270.0 ± NA
SecondaryThe Number of Units of Red Blood Cell (RBC) Transfusions by Cycle

The number of units of RBC received 56 days prior to treatment, considered the baseline period (baseline period defined as the screening period before the date of the first dose of azacitidine; any laboratory and blood transfusion data reported on the day of the first dose of azacitidine was considered to be baseline data) and during study was standardized per 28 days and summarized by cycle for RBC. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length.

Time frame:
Up to cycle 27; The on-treatment period was considered the period from the date of first dose to the last treatment study visit; Up to 29 January 2015; 894 days
Reported as:
Mean · Units of RBC Transfusions
The Number of Units of Red Blood Cell (RBC) Transfusions by Cycle
Units of RBC TransfusionsAzacitidine
Baseline N = 722.3 ± 3.55
Overall Post-Baseline Average N = 723.5 ± 3.88
Overall Change from Baseline N = 721.2 ± 4.34
Cycle 1 N = 723.6 ± 3.41
Cycle 23.6 ± 4.88
Cycle 33.0 ± 3.68
Cycle 42.7 ± 3.73
Cycle 52.5 ± 3.94
Cycle 62.0 ± 3.46
Cycle 71.7 ± 3.84
Cycle 81.7 ± 2.68
Cycle 90.9 ± 1.56
Cycle 101.2 ± 2.25
Cycle 111.3 ± 1.97
Cycle 121.1 ± 2.21
Cycle 131.2 ± 2.62
Cycle 140.4 ± 1.05
Cycle 151.1 ± 2.07
Cycle 160.9 ± 1.61
Cycle 171.2 ± 3.28
Cycle 181.6 ± 3.07
Cycle 190.8 ± 1.37
Cycle 201.1 ± 1.42
Cycle 210.4 ± 0.62
Cycle 22 N0 ± NA
Cycle 230.0 ± NA
Cycle 240.0 ± NA
Cycle 250.0 ± NA
Cycle 260.0 ± NA
Cycle 270.0 ± NA
SecondaryThe Number of RBC Transfusions by Cycle

The number of RBC transfusions received 56 days prior to treatment, considered the baseline period (baseline period defined as the screening period before the date of the first dose of azacitidine; any laboratory and blood transfusion data reported on the day of the first dose of azacitidine was considered to be baseline data) and during study was standardized per 28 days and summarized by cycle for platelets. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length.

Time frame:
Up to cycle 27; The on-treatment period was considered the period from the date of first dose to the last treatment study visit; Up to 29 January 2015; 894 days
Reported as:
Mean · RBC Transfusions
The Number of RBC Transfusions by Cycle
RBC TransfusionsAzacitidine
Baseline N = 721.1 ± 1.79
Overall Post-Baseline Average N = 721.6 ± 1.97
Overall Change from Baseline N = 720.5 ± 2.12
Cycle 1 N = 721.7 ± 1.64
Cycle 21.7 ± 2.56
Cycle 31.4 ± 1.81
Cycle 41.2 ± 1.73
Cycle 51.1 ± 1.81
Cycle 60.9 ± 1.63
Cycle 70.8 ± 1.97
Cycle 80.8 ± 1.23
Cycle 90.4 ± 0.74
Cycle 100.5 ± 0.94
Cycle 110.5 ± 0.78
Cycle 120.4 ± 0.87
Cycle 130.5 ± 0.94
Cycle 140.2 ± 0.53
Cycle 150.4 ± 0.77
Cycle 160.4 ± 0.57
Cycle 170.3 ± 0.91
Cycle 180.7 ± 1.17
Cycle 190.4 ± 0.64
Cycle 200.6 ± 0.71
Cycle 210.2 ± 0.31
Cycle 220.0 ± NA
Cycle 230.0 ± NA
Cycle 240.0 ± NA
Cycle 250.0 ± NA
Cycle 260.0 ± NA
Cycle 270.0 ± NA
SecondaryThe Number of Infections (Post-baseline Average) Requiring Intravenous (IV) Antibiotics, Anti-fungals, or Antivirals by Cycle

The on-treatment adverse event of infection requiring IV antibiotics, antifungals, or antivirals per 28 days/cycle. The overall post-baseline average is the average of number of infections requiring IV antibiotics or IV antiviral per 28 days/cycle.

Time frame:
Up to cycle 27; The on-treatment period was considered the period from the date of first dose to the last treatment study visit; Up to 29 January 2015; 894 days
Reported as:
Mean · Infections
The Number of Infections (Post-baseline Average) Requiring Intravenous (IV) Antibiotics, Anti-fungals, or Antivirals by Cycle
InfectionsAzacitidine
Baseline N = 720.0 ± 0.20
Overall Post Baseline Average N = 720.6 ± 1.43
Overall Change from Baseline N =720.5 ± 1.45
Cycle 1 N = 720.6 ± 1.32
Cycle 20.5 ± 1.67
Cycle 30.4 ± 0.86
Cycle 40.5 ± 1.03
Cycle 50.4 ± 0.72
Cycle 60.2 ± 0.61
Cycle 70.3 ± 1.01
Cycle 80.2 ± 0.47
Cycle 90.1 ± 0.32
Cycle 100.2 ± 0.44
Cycle 110.1 ± 0.31
Cycle120.1 ± 0.27
Cycle 130.1 ± 0.24
Cycle 14 150.1 ± 0.32
Cycle 150.3 ± 0.70
Cycle 160.3 ± 0.42
Cycle 170.4 ± 0.75
Cycle 180.4 ± 0.74
Cycle 190.2 ± 0.41
Cycle 200.0 ± 0.00
Cycle 210.0 ± 0.00
Cycle 220.9 ± NA
Cycle 231.0 ± NA
Cycle 240.0 ± NA
Cycle 250.0 ± NA
Cycle 26 N0.0 ± NA
Cycle 270.0 ± NA
SecondaryKaplan Meier Estimates for Overall Survival (OS)

Overall survival is defined as time to death from any cause, is calculated using date of first dose and date of death, or date of last follow-up for censored participants. Those, who die regardless of the cause of death, will be considered to have an event.

Time frame:
Until the end of the survival follow-up period; Up to data cut-off of 29 January 2015; 894 days
Reported as:
Number · months
Kaplan Meier Estimates for Overall Survival (OS)
monthsAzacitidine
Median OS22.0 (15.1 to NA)
25th percentile OS8.5 (6.1 to 13.8)
75th Percentile OSNA (24.2 to NA)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAE) During the Parent Phase

A treatment-emergent adverse events (TEAE) was defined as AEs with an onset date on or after the date of first dose and within 28 days after the date of the last dose. Any AE that occurred beyond this timeframe and was assessed by the investigator as possibly related to study drug was considered treatment-emergent. The intensity and severity of AEs was assessed by the investigator according to the Common Terminology Criteria for Adverse Event (CTCAE) Version 4.0. For any AEs not listed in the CTCAE grading system, the intensities of these events was assessed by the Investigator using the 5-point scale: Grade 1 = Mild, Grade 2 = Moderate; Grade 3 = Severe, Grade 4 = Life threatening, Grade 5 = Death. An SAE is any AE occurring that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and constitutes an important medical event.

Time frame:
Up to 29 January 2015; from the first dose of study drug to 28 days after the date of the last dose of study drug (maximum time on study was 244 days)
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Parent Phase
participantsAzacitidine
≥ 1 TEAE72
≥ 1 Grade 3 or 4 TEAE70
≥ 1 TEAE related to study drug68
≥ 1 Grade 3 or 4 TEAE related to study drug59
≥ 1 serious TEAE38
≥ 1 Grade 3 or 4 serious TEAE33
≥ 1 serious TEAE related to study drug28
≥ 1 TEAE leading to discontinuation of study drug14
≥ 1 TEAE leading to dose reduction of study drug19
≥1 TEAE leading to dose interruption of study drug49
≥1 TEAE leading to dose reduction/interruption50
≥1 TEAE with outcome of death11
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Azacitidine

Area under the plasma concentration-time curve from time zero to infinity (AUC∞) following multiple doses of Azacitidine on Day 7; if possible, the area under the concentration-time curve from time zero to infinity, calculated by the linear trapezoidal rule and extrapolated to infinity was calculated according to the following equation: AUC∞ = AUCt + (Ct/ λz ), where Ct is the last quantifiable concentration. No AUC extrapolation will be performed with unreliable λz. If % AUC extrapolated is ≥ 25%, AUC∞ will not be reported

Time frame:
PK blood samples collected at 0.25, 0.5, 1,2,3,4, 6 and 8 hours after azacitidine administration on Day 7
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Azacitidine
ng*h/mLAzacitidine
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Azacitidine1172.6 ± 18.0
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Azacitidine

Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear trapezoidal rule when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing.

Time frame:
PK blood samples collected at 0.25, 0.5, 1,2,3,4, 6 and 8 hours after azacitidine administration on Day 7
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Azacitidine
ng*h/mLAzacitidine
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Azacitidine1161.9 ± 17.7
SecondaryMaximum Observed Plasma Concentration (Cmax) of Azacitidine

The observed maximum plasma concentration obtained directly from the observed concentration versus time data.

Time frame:
PK blood samples collected at 0.25, 0.5, 1,2,3,4, 6 and 8 hours after azacitidine administration on Day 7
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Azacitidine
ng/mLAzacitidine
Maximum Observed Plasma Concentration (Cmax) of Azacitidine1264.6 ± 30.7
SecondaryTime to Maximum Plasma Concentration (Tmax) of Azacitidine

Time to maximum observed plasma concentration obtained directly from the observed concentration versus time data.

Time frame:
PK blood samples collected at 0.25, 0.5, 1,2,3,4, 6 and 8 hours after azacitidine administration on Day 7
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax) of Azacitidine
hoursAzacitidine
Time to Maximum Plasma Concentration (Tmax) of Azacitidine0.25 ± 27.66
SecondaryTerminal Phase of Half-life (T1/2) of Azacitidine

The apparent terminal half-life was calculated according to the following equation t½ = 0.693/λz.

Time frame:
PK blood samples collected at 0.25, 0.5, 1,2,3,4, 6 and 8 hours after azacitidine administration on Day 7
Reported as:
Geometric mean · hours
Terminal Phase of Half-life (T1/2) of Azacitidine
hoursAzacitidine
Terminal Phase of Half-life (T1/2) of Azacitidine0.8 ± 69.0
SecondaryApparent Total Plasma Clearance (CL/F) of Azacitidine

Apparent total plasma clearance (CL/F) of Azacitidine was calculated as Dose/AUC∞

Time frame:
PK blood samples collected at 0.25, 0.5, 1,2,3,4, 6 and 8 hours after azacitidine administration on Day 7
Reported as:
Geometric mean · Liters/hours
Apparent Total Plasma Clearance (CL/F) of Azacitidine
Liters/hoursAzacitidine
Apparent Total Plasma Clearance (CL/F) of Azacitidine107.2 ± 19.1
SecondaryApparent Volume of Distribution (Vd/F) of Azacitidine

Apparent volume of distribution, was calculated according to the equation: Vd/F = (CL/F)/λz

Time frame:
PK blood samples collected at 0.25, 0.5, 1,2,3,4, 6 and 8 hours after azacitidine administration on Day 7
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution (Vd/F) of Azacitidine
LitersAzacitidine
Apparent Volume of Distribution (Vd/F) of Azacitidine121.5 ± 65.1
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAE) During the Extension Phase

A treatment-emergent adverse events (TEAE) was defined as AEs with an onset date on or after the date of first dose and within 28 days after the date of the last dose. Any AE that occurred beyond this timeframe and was assessed by the investigator as possibly related to study drug was considered treatment-emergent. The intensity and severity of AEs was assessed by the investigator according to the Common Terminology Criteria for Adverse Event (CTCAE) Version 4.0. For any AEs not listed in the CTCAE grading system, the intensities of these events was assessed by the Investigator using the 5-point scale: Grade 1 = Mild, Grade 2 = Moderate; Grade 3 = Severe, Grade 4 = Life threatening, Grade 5 = Death. An SAE is any AE occurring that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and constitutes an important medical event.

Time frame:
Up to final data cut off date of 25 April 2018; from the first dose of study drug extesnion of 29 December 2014 to 28 days after the date of the last dose of study drug; median duration of any dose of study drug was 169 days
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Extension Phase
participantsAzacitidine
≥ 1 TEAE14
≥ 1 TEAE related to study drug8
≥ 1 Grade 3 or 4 TEAE13
≥ 1 Grade 3 or 4 TEAE related to study drug6
≥ 1 serious TEAE5
≥ 1 serious TEAE related to study drug1
≥ 1 Grade 3 or 4 serious TEAE5
≥1 TEAE leading to dose interruption of study drug4
≥1 TEAE leading to dose reduction/interruption4

Adverse events

Collected over Azacitidine Exposure across all cycles: median duration of azacitidine treatment was 786 days (range 428 to 1507).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Azacitidine - Parent Phase13/72 (18.1%)38/72 (52.8%)72/72 (100%)
Azacitdine - Extension Phase0/15 (0%)5/15 (33.3%)14/15 (93.3%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventAzacitidine - Parent PhaseAzacitdine - Extension Phase
PneumoniaInfections and infestations11/721/15
AnaemiaBlood and lymphatic system disorders1/722/15
Lung infectionInfections and infestations2/722/15
Febrile neutropeniaBlood and lymphatic system disorders5/720/15
Cardiac failureCardiac disorders2/721/15
ThrombocytopeniaBlood and lymphatic system disorders4/721/15
ErythropeniaBlood and lymphatic system disorders0/721/15
EnteritisGastrointestinal disorders0/721/15
Rhinitis AllergicRespiratory, thoracic and mediastinal disorders0/721/15
Renal Failure, AcuteRenal and urinary disorders0/721/15
Most frequent other events
Showing 10 of 79
Most frequent other events
EventAzacitidine - Parent PhaseAzacitdine - Extension Phase
ThrombocytopeniaBlood and lymphatic system disorders52/7210/15
LeukopeniaBlood and lymphatic system disorders48/7210/15
NeutropeniaBlood and lymphatic system disorders48/726/15
AnaemiaBlood and lymphatic system disorders38/726/15
Upper respiratory tract infectionInfections and infestations27/721/15
ConstipationGastrointestinal disorders22/721/15
PyrexiaGeneral disorders21/722/15
NauseaGastrointestinal disorders19/723/15
PneumoniaInfections and infestations19/721/15
GingivitisInfections and infestations16/722/15

Baseline characteristics

ITT includes all participants who had been screened and enrolled into the study.

Age, Continuous
Age, Continuous(years)Azacitidine
Mean54.3 ± 11.78
Sex: Female, Male
Sex: Female, Male(Participants)Azacitidine
Female34
Male38
International Prognostic Scoring System (IPSS) Risk Classification
International Prognostic Scoring System (IPSS) Risk Classification(Participants)Azacitidine
Low (0)0
Intermediate 1 (0.5-1.0)0
Intermediate 2 (1.5-2.0)47
High (>=2.5)25
French-American-British classification (FAB)
French-American-British classification (FAB)(Participants)Azacitidine
RAEB=Refractory anemia with excess blasts63
RAEB in transformation8
Modified CMML=Chronic myelomonocytic leukemia1
MDS World Health Organization (WHO) Classification
MDS World Health Organization (WHO) Classification(Participants)Azacitidine
RAEB-1=Refractory anemia with excess blasts14
RAEB -2 with MPD=Myeloproliferative disease50
Acute Myelogenous Leukemia (AML)7
CMML1
MDS and myeloproliferative disease (MPD)0
08

Study locations

11 sites
  • Peking University People's Hospital
    Beijing, 100044, China
  • The 301 Hospital- Chinese PLA General Hospital
    Beijing, 300200, China
  • The Third Hospital of Peking University
    Beijing, China
  • West China Hospital of Sichuan University
    Chengdu, 610041, China
  • Guangdong General Hospital
    Guangzhou, 510080, China
  • 1st Hospital Zhejiang University (The First Affiliated Hospital of Zhejiang University )
    Hangzhou, 310003, China
  • Ruijin Hospital Shanghai Jiaotong University
    Shanghai, 200025, China
  • Shanghai 6th Hospital
    Shanghai, 200233, China
  • The 1st Hospital of Soochow University
    Suzhou, 215006, China
  • Blood Disease Hospital, Chinese Academy of Medical Science and Peking Union Medical College
    Tianjin, 300041, China
  • Wuhan Union Hospital
    Wuhan, 430000, China
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2012 to primary completion in Jan 2015, 30 months.

Results were first posted in Feb 2016, 1 year 1 month after primary completion.

Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 30 months is below that.

Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2012
First posted
May 16, 2012
StartActual
Jul 24, 2012
Primary completionActual
Jan 29, 2015
CompletionActual
Mar 13, 2018
Results first posted
Feb 29, 2016
Last update
Mar 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01599325
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
May 16, 2012
Start date
Jul 24, 2012
Primary completion
Jan 29, 2015
Completion
Mar 13, 2018
Results posted
Feb 29, 2016
Last update
Mar 19, 2019

Study contacts

C L Beach
study director · Celgene

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azacitidine

Start the discussion